LIQUID BIOPSY FOR EARLY, NON‐INVASIVE DIAGNOSIS OF EBV‐POSITIVE BURKITT LYMPHOMA IN RESOURCE LIMITED SETTINGS

Abstract

33/36 negative PET-CTs (91.7%) were consistent with a LiqBio-MRD-determination, and 11/13 positive PET-CTs (85%) were LiqBio-MRD +. Patients with PET-CT positive but LiqBio-MRD-(n = 2) resulted as false positive PET/CT (cervical mass confirmed by biopsy and mesenteric mass becoming negative in the next PET/CT analysis). Furthermore, patients with PET-CT negative and LiqBio-MRD + (n = 3) presented progression. Conclusions: In the case of FL undergoing CAR T-cell, this is the first in FL study demonstrating the utility of a non-invasive personalized MRD evaluation in liquid biopsy. Our LiqBio-MRD test is able to predict LBCL and FL outcome and could be of high utility to detect false positives or negatives PET/CT assessments during follow-up. No conflicts of interests pertinent to the abstract. 238 |